AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
DBV Technologies S.A.
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG0076D3TV8
9.75▲ 0.07 (0.72%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
9.68
Day's Range
9.45 – 9.78
52-Week Range
8.63 – 26.19
Volume
254.3K
Avg Volume
380.0K
Share Statistics
Shares Outstanding
Employees
125
Exchange
XNAS
Listed
2014-10-22
Share count as of July 16, 2026

DBV Technologies S.A. (DBVT) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about DBV Technologies S.A. (DBVT)
What is DBV Technologies S.A.'s Market Cap?
DBV Technologies S.A.'s Market Cap is $2.9B, based on as-reported figures from SEC (XBRL) filings.
What is DBV Technologies S.A.'s Price / Sales?
DBV Technologies S.A.'s Price / Sales is 573.2×, based on as-reported figures from SEC (XBRL) filings.
What is DBV Technologies S.A.'s Revenue (TTM)?
DBV Technologies S.A.'s Revenue (TTM) is $5.0M, based on as-reported figures from SEC (XBRL) filings.
What is DBV Technologies S.A.'s Net Income (TTM)?
DBV Technologies S.A.'s Net Income (TTM) is -$175.9M, based on as-reported figures from SEC (XBRL) filings.
What is DBV Technologies S.A.'s EBITDA?
DBV Technologies S.A.'s EBITDA is -$174.9M, based on as-reported figures from SEC (XBRL) filings.
What is DBV Technologies S.A.'s Diluted EPS (TTM)?
DBV Technologies S.A.'s Diluted EPS (TTM) is -0.59, based on as-reported figures from SEC (XBRL) filings.
What is DBV Technologies S.A.'s EBITDA Margin?
DBV Technologies S.A.'s EBITDA Margin is -3472.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · DBVTAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating income—
YoY growth-53.3%—+26.2%+158.8%
Operating expenses
Research and development expenses—
Sales and marketing expenses—
General and administrative expenses—
Total Operating expenses—
% of revenue-7328.6%—-7084.5%-1335.7%
Loss from operations—
% of revenue-7228.6%—-6984.7%-1235.7%
Financial income (expense)—
Loss before taxes—
Income tax—
Net loss
% of revenue-7200.0%—-6950.2%-1195.5%
Basic net loss per share attributable to shareholders (in dollars per share)—
Diluted net loss per share attributable to shareholders (in dollars per share)—